Multiple sclerosis
Four Xenia Property Group employees completed a charity fitness challenge in Manchester to support the MS Society. Head of lettings Jennifer Brown, senior lettings negotiator Liam Lowe, senior estates manager Jae Manwaring and marketing coordinator Kirsty Johnston took part in the first DEKA IGNITE team event at Manchester Central. The challenge featured 10 running and [...]
An eight-year £2.72m AI project aims to improve personalised MS care by learning from information already collected in hospitals. The Wellcome-funded Data-driven Representation Learning for Equitable, Personalised Care in Multiple Sclerosis project, known as DreaMS, will develop AI tools to make better use of decades of existing hospital data. The project will [...]
Certain diets may support cognition in people with multiple sclerosis, although the evidence remains too limited for firm recommendations. Studies of the low-fat Swank and Wahls diets reported improvements in processing speed and self-perceived cognitive function. Evidence for the Mediterranean diet was mixed, while small studies suggested possible benefits from ketogenic diets and time-restricted eating. [...]
Word-finding problems affect one in four people with MS and are linked to cognition rather than fatigue or depression, a study suggests. People with cognitive impairment were nearly five times more likely to experience difficulties retrieving words than those without cognitive impairment. The symptom was not associated with fatigue or depression. “Findings [...]
AI has revealed previously undetectable brain lesions in people with MS, in research that could change how the condition is monitored. Multiple sclerosis, commonly known as MS, is a debilitating condition in which the immune system mistakenly attacks the nervous system. It affects around 150,000 people in the UK. It can cause fatigue, vision problems, [...]
MS affects social life and work for many people, while finances and education are also affected, a nationwide study has found. More than half of participants said the condition affected their social lives, while almost half reported an impact on their work. The findings suggest the effects of the neurological condition extend beyond physical symptoms [...]
The final patient has begun dosing in a trial of a nasal therapy for non-active secondary progressive multiple sclerosis. The phase 2a study is evaluating the safety, tolerability and efficacy of foralumab compared with a placebo, an inactive treatment. Headline results are expected later this year and are planned for presentation at the joint ACTRIMS-ECTRIMS [...]
The European Commission (EC) has approved Cenrifki for adults with secondary progressive multiple sclerosis (MS) who had no relapses in the previous two years. The decision follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use. Sanofi said Cenrifki, also known as tolebrutinib, is the first disease-targeting therapy approved [...]
The US FDA has cleared PTD802 for a first-in-human trial, allowing Pheno Therapeutics to move the experimental MS treatment into clinical testing. The Investigational New Drug clearance allows the company to proceed with a clinical trial in the US. The first study would assess the safety and tolerability of the treatment in healthy volunteers. [...]
An exercise hormone may ease MS symptoms by protecting nerve cells from damage, early research in mice suggests. Irisin, a hormone released during exercise, appeared to directly shield neurons from damage in a mouse model of multiple sclerosis. An experimental gene therapy raised blood levels of the hormone, reducing clinical disability and limiting nerve cell [...]
